ReviewPublic health action2013
New screening technologies for type 2 diabetes mellitus appropriate for use in tuberculosis patients.
Review in Public health action, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Is there an effect of glucose lowering treatment on incidence and prognosis of tuberculosis? A systematic review.Current diabetes reports · 2014Pooled it
- TB-diabetes co-morbidity in Ghana: The importance of Mycobacterium africanum infection.PloS one · 2019Trial
- Insight on Infections in Diabetic Setting.Biomedicines · 2023Review
- Article
- Rethinking the syndemic of tuberculosis and dysglycaemia: a Kenyan perspective on dysglycaemia as a neglected risk factor for tuberculosis.Bulletin of the National Research Centre · 2023Review
- Recent Developments in Biomarkers for Diagnosis and Screening of Type 2 Diabetes Mellitus.Current diabetes reports · 2022Review
- Global, regional, and national prevalence of diabetes mellitus in patients with pulmonary tuberculosis: a systematic review and meta-analysis.Diabetology & metabolic syndrome · 2021Article
- Tuberculosis, Human Immunodeficiency Virus, and the Association With Transient Hyperglycemia in Periurban South Africa.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Gold Nanostar Colorimetric Detection of Fructosyl Valine as a Potential Future Point of Care Biosensor Candidate for Glycated Haemoglobin Detection.Biosensors · 2019Article
- [Co-management of tuberculosis and diabetes: an integrative reviewManejo integrado de la tuberculosis y la diabetes: revisión integrativa].Revista panamericana de salud publica = Pan American journal of public health · 2019Review
- Diabetes and pre-diabetes in tuberculosis patients in western Kenya using point-of-care glycated haemoglobin.Public health action · 2017Article
- Double Trouble: Prevalence and Factors Associated with Tuberculosis and Diabetes Comorbidity in Bangladesh.PloS one · 2016Article
- SCALING UP NON-COMMUNICABLE DISEASE CONTROL: LESSONS TO BE LEARNT FROM THE INFECTIOUS DISEASE PARADIGM IN KENYA.East African medical journal · 2015Article
- Diabetes mellitus and tuberculosis: programmatic management issues.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2015Article
- Clinical management of concurrent diabetes and tuberculosis and the implications for patient services.The lancet. Diabetes & endocrinology · 2014Review
- Changes in glycosylated haemoglobin and treatment outcomes in patients with tuberculosis in Iran: a cohort study.Journal of diabetes and metabolic disorders · 2014Article
- Taking on the diabetes-tuberculosis epidemic in India: paving the way through operational research.Public health action · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus (DM), which is epidemic in low- and middle-income countries (LMICs), may threaten gains made in tuberculosis (TB) control, as DM is both a major risk factor for developing active TB and it can lead to adverse TB treatment outcomes. Despite World Health Organization guidance that all TB patients should be screened for DM, most facilities in LMICs that manage TB patients do not currently perform screening for DM, due in part to the cost and complexity involved. DM screening is further complicated by the presentation of transient hyperglycemia in many TB patients, as well as differences in diabetes risk factors (e.g., body mass index) between TB patients and the general public. In this article, we review existing and new technologies for DM screening that may be more suitable for TB patients in LMICs. Such methods should be rapid, they should not require fasting, and they should allow the provider to differentiate between transient and longer-term hyperglycemia, using inexpensive tools that require little training and no specialized infrastructure. Several methods that are currently under development, such as point-of-care glycated hemoglobin and glycated albumin assays, non-invasive advanced glycation end-product readers, and sudomotor function-based screening devices, offer interesting performance characteristics and warrant evaluation in populations with TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.